Discover the Investment Opportunities in Junior BiotechnologyLearn more about this firm
Thursday, October 22, 2020
2:00 PM EDT | 11:00 AM PDT
Summary Already Registered? Click here »
In the midst of a global pandemic there has never been more focus on the companies that are developing the vaccines, and treatments to help people live longer, and healthier lives. Investors have already shown interest and commitment to investing in biotechnology with over $20 Billion of capital already allocated to biotechnology ETFs. Please join Defiance ETFs, and Nasdaq in discussing the most recent way to invest in biotechnology with the Defiance Nasdaq Junior Biotechnology ETF-ticker: IBBJ. IBBJ allows investors to gain targeted exposure to mid, and small-cap biotechnology equities and offers more of a “pure-play” way to access research and development spending in biotech.
What you will learn:
- What defines junior biotechnology equities?
- The investment case for mid and small-cap “junior” biotechnology equities
- Why IBBJ makes sense for targeted exposure to junior biotechnology
Specialist in Index Research & Development
Mark Marex works as a Specialist in Index Research & Development, splitting his efforts between producing original content in support of existing index products, as well as developing new indexes for launch and commercialization. Before joining Nasdaq Global Indexes in 2019, Mark was an emerging fund manager of a systematic long/short US large-cap equity strategy, and co-founded Roundtree Capital Management in 2016. Prior to that, Mark spent eight years at Citigroup in New York, working as a Product Manager of FX in the Investor Services business; as a Vice President of Client Strategy & Analytics in the Investment Banking division; and when he first started in 2008, as a Product Controller in Structured Credit.
Mark graduated with a Bachelor of Science in Economics from Duke University in 2008, and has been a CFA charter holder since 2012.He is passionate about innovation in the world of indexing, ETFs, and quantitative investing. He resides in Brooklyn, NY with his fiancée.
Paul brings more than 18 years of ETF experience to his role as President of Defiance ETFs. Paul joined Defiance in August of 2018.
Prior to joining Defiance ETFs, Paul spent over 10 years of his career with BlackRock (formerly BGI), and iShares. While at BlackRock, Paul was responsible for ETF distribution, and sales leadership within the US Wealth Advisory iShares business. Paul also held roles responsible for mutual funds, SMA, and closed end distribution at BlackRock. Prior to joining BlackRock, Paul was an Assistant VP at Merrill Lynch, and spent six years at SEI where he was dedicated to the iShares business from 2001-2007.
Paul earned a B.S. in Finance and Marketing from Florida State University, as well as an M.B.A. from Saint Joseph’s University Haub School of Business. He also currently holds the Certified Investment Management Analyst (CIMA®), and Chartered Alternative Investment Analyst (CAIA) designations; in addition to the Series 7, 24, 51, 63, and 65 licenses.
CEO and Founder
Robert Huebscher is the founder and CEO of Advisor Perspectives and serves as its editor-in-chief. He is a frequent speaker at industry conferences and has written extensively on topics including investment management, portfolio construction, financial planning and global economics.